午后，直线涨停！重磅消息，引爆！

Core Viewpoint - The article highlights significant developments in Chongqing, including a surge in local stocks and the introduction of measures to support the high-quality development of innovative drugs, driven by administrative adjustments and strategic initiatives in the pharmaceutical sector [1][8]. Group 1: Stock Market Reaction - On November 6, local stocks in Chongqing experienced a collective surge, with companies like Chongqing Construction, Caixin Development, and Yude Development hitting the daily limit [2][3]. - The stock market reaction was attributed to a news conference announcing administrative adjustments in several districts, including the Liangjiang New Area and Jiangbei District [2][4]. Group 2: Administrative Adjustments - The administrative adjustments aim to optimize the spatial structure and urban functions of the central urban area, enhancing coordination and efficiency in urban planning [4][5]. - The first major adjustment involves the establishment of Liangjiang New Area, which will incorporate the former Jiangbei and Yubei districts, focusing on industrial clustering and functional synergy [5][6]. - The second adjustment transfers several towns from Yubei District to Beibei District, enhancing ecological and cultural resource management [6][7]. Group 3: Innovative Drug Development Measures - The Chongqing government issued measures to support the innovative drug sector, aiming for 1-3 new drug approvals annually by 2027, with a total target of 10 innovative drugs [1][8]. - Financial incentives include up to 20% funding support for various stages of drug development, with maximum support amounts ranging from 200 million to 1 billion yuan depending on the phase [8][10]. - Additional rewards for successful drug commercialization include 1 million yuan for innovative drugs and 500,000 yuan for improved drugs [10][12]. Group 4: Financial and Technological Support - The measures emphasize enhancing financial support through new policy tools and encouraging banks to provide long-term credit and other financing options for innovative drug development [12]. - The integration of artificial intelligence in drug development is promoted, with initiatives to create a comprehensive AI-driven drug research ecosystem [11][12].